wang wei

Author    Correspondence author
Journal of Vaccine Research, 2024, Vol. 14, No.   
Received: 01 Jan., 1970    Accepted: 01 Jan., 1970    Published: 11 Oct., 2024

The development of cancer vaccines has been significantly advanced by the incorporation of adjuvants, which enhance the immunogenicity of tumor antigens and improve clinical efficacy. Adjuvants can be broadly categorized into those that act as depots for antigens and those that function as immunostimulants. Recent research highlights the importance of combinatorial adjuvant strategies that target multiple branches of the immune response to overcome challenges such as poor antigen immunogenicity and tumor immune evasion. Personalized cancer vaccines, which utilize individualized tumor-specific antigens, have shown promise, particularly when combined with novel adjuvants and delivery systems. Additionally, the mode of administration, such as intratumoral delivery, has been shown to significantly enhance the immune response compared to traditional methods. The role of dendritic cells in cross-presentation and the activation of cytotoxic T cells is crucial for the efficacy of these vaccines. This study discusses the various adjuvant strategies, including chemical and biological approaches, that are being explored to enhance the potency and effectiveness of cancer vaccines.